Any progress in pancreatic cancer? Well, but progress for Acta Oncologica

References

• Simianu V, Zyromski NJ, Nakeeb A, Lillemoe KD. Pancreatic cancer: Progress made. Acta Oncol 2010;49:407–17.
   PubMed Web of Science ®Google Scholar
• Glimelius B. Oncology in the Nordic countries–the role of Acta Oncologica? Acta Oncol 2002;41:3–5.
   PubMed Web of Science ®Google Scholar
• Ringborg U. Swedish oncology. Past–present–future. Acta Oncol 2008;47:171–5.
   PubMed Web of Science ®Google Scholar
• Smith N, Brown G. Preoperative staging in rectal cancer. Acta Oncol 2008;47:20–31.
   PubMed Web of Science ®Google Scholar
• Hardell L. Pesticides, soft-tissue sarcoma and non-Hodgkin lymphoma–historical aspects on the precautionary principle in cancer prevention. Acta Oncol 2008;47:347–54.
   PubMed Web of Science ®Google Scholar
• Adami HO. The prostate cancer pseudo-epidemic. Acta Oncol 2010;49:298–304.
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887–907.
   PubMed Web of Science ®Google Scholar
• Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, . Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918–26.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, . Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267–77.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Jelic S. Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):37–40.
   PubMedGoogle Scholar
• Burris HAIII, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–13.
   PubMed Web of Science ®Google Scholar
• Permert J, Hafström Lo, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 2001;40:361–70.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–6.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, . Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009;27:5660–9.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Kurzrock R. Cancer: The road to Amiens. J Clin Oncol 2009;27:328–33.
   PubMed Web of Science ®Google Scholar
• Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009;27:5868–73.
   PubMed Web of Science ®Google Scholar
• Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, . Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol 2009 DOI: 10.1200/JCO. 2009.22.8429.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Lahn M, Gawande S, Cleverly A, Darstein C, Musib L, . A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic met-astatic colorectal cancer. Ann Oncol 2009 (in press) DOI:10.1093/annonc/mdp521.
   Web of Science ®Google Scholar
• Glimelius B, Spindler KL, Frodin JE, Berglund A, Bystrom P, Qvortrup C, . Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study. Ann Oncol 2009 (in press) DOI:10.1093/annonc/mdp526.
   Web of Science ®Google Scholar
• Muren LP, Petersen JB, Hansen J, Hafslund R. Medical physics in the Nordic countries: The past, the present and the future. Acta Oncol 2009;48:165–8.
   PubMed Web of Science ®Google Scholar
• Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparen P, Tryggvadottir L, . Occupation and cancer– follow-up of 15 million people in five Nordic countries. Acta Oncol 2009;48:646–790.
   PubMed Web of Science ®Google Scholar
• Brundage MD, Feldman-Stewart D, Tishelman C. How do interventions designed to improve provider-patient communication work? Illustrative applications of a framework for communication. Acta Oncol 2010;49:136–43.
   PubMed Web of Science ®Google Scholar
• Street AF, Horey D. The State of the Science: Informing choices across the cancer journey with public health mechanisms and decision processes. Acta Oncol 2010;49:144–52.
   PubMed Web of Science ®Google Scholar
• Sprangers MA. Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol 2010;49:155–63.
   PubMed Web of Science ®Google Scholar
• Glimelius B. The dream of a philologist. Acta Oncol 2008;47:991–3.
   PubMed Web of Science ®Google Scholar